Please login to the form below
Aliqopa
This page shows the latest Aliqopa news and features for those working in and with pharma, biotech and healthcare.
FDA clears Novartis’ new breast cancer drug Piqray
Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and Verastem’s Copiktra (duvelisib) – but so far they have been unable to
Latest news
-
Novartis claims a rare win at ESMO for PI3K inhibitor class
Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently
-
Novartis considers filings for PI3K drug in breast cancer
years and was recently joined on the market by Bayer’s Aliqopa (copanlisib), also for blood cancers.
-
Bayer bags speedy US approval for lymphoma drug Aliqopa
The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Aliqopa (copanlisib) has been given a conditional green light as a third-line treatment for patients with relapsed
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- Gut instincts lead Takeda to GI pipeline success
- AbbVie, Amgen and Takeda team up for joint COVID-19 trial
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
